MA53904A - Composés contenant du deutérium - Google Patents

Composés contenant du deutérium

Info

Publication number
MA53904A
MA53904A MA053904A MA53904A MA53904A MA 53904 A MA53904 A MA 53904A MA 053904 A MA053904 A MA 053904A MA 53904 A MA53904 A MA 53904A MA 53904 A MA53904 A MA 53904A
Authority
MA
Morocco
Prior art keywords
compounds containing
containing deuterium
deuterium
compounds
Prior art date
Application number
MA053904A
Other languages
English (en)
Inventor
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of MA53904A publication Critical patent/MA53904A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053904A 2018-10-18 2019-10-17 Composés contenant du deutérium MA53904A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds

Publications (1)

Publication Number Publication Date
MA53904A true MA53904A (fr) 2021-08-25

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053904A MA53904A (fr) 2018-10-18 2019-10-17 Composés contenant du deutérium

Country Status (19)

Country Link
US (2) US12152087B2 (fr)
EP (1) EP3866931B1 (fr)
JP (2) JP7603199B2 (fr)
KR (1) KR102848971B1 (fr)
CN (1) CN112930214B (fr)
AU (1) AU2019362389B2 (fr)
BR (1) BR112021007060A2 (fr)
CA (1) CA3116198A1 (fr)
DK (1) DK3866931T3 (fr)
ES (1) ES2942468T3 (fr)
FI (1) FI3866931T3 (fr)
HU (1) HUE061801T2 (fr)
IL (1) IL282231B2 (fr)
MA (1) MA53904A (fr)
MX (1) MX2021004474A (fr)
PL (1) PL3866931T3 (fr)
SG (1) SG11202103726RA (fr)
WO (1) WO2020079165A1 (fr)
ZA (1) ZA202102492B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (fr) * 2021-06-01 2025-05-21 Synthon B.V. Procédé de préparation de melflufène ou d'un sel de celui-ci
WO2023281007A1 (fr) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufène destiné à être utilisé dans le traitement du myélome multiple
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (fr) * 2024-09-13 2026-03-19 Oncopeptides Ab Dérivés de bis-chloroéthylamino pour le traitement de la leucémie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
CA2736409C (fr) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Inhibiteurs benzoquinoline du transporteur de monoamines vesiculaire 2
CA2801061A1 (fr) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Inhibiteurs benzoquinolone de vmat2
SI2701720T1 (sl) 2011-04-28 2017-11-30 Oncopeptides Ab Liofilizirani pripravek citotoksičnih dipeptidov
CA2883641C (fr) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Pharmacocinetiques de formulations d'inhibiteurs de benzoquinoline deutere du transporteur 2 de monoamine vesiculaire
WO2014065751A1 (fr) 2012-10-26 2014-05-01 Oncopeptides Ab Préparations lyophilisées de melphalan flufénamide
WO2014120654A1 (fr) 2013-01-31 2014-08-07 Auspex Pharmaceuticals, Inc. Inhibiteurs de vmat2 de type benzoquinolone
JP6704252B2 (ja) 2013-02-05 2020-06-03 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
CN104725380B (zh) 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Also Published As

Publication number Publication date
IL282231A (en) 2021-05-31
KR102848971B1 (ko) 2025-08-21
KR20210078487A (ko) 2021-06-28
JP7603199B2 (ja) 2024-12-20
ZA202102492B (en) 2024-04-24
US20210388024A1 (en) 2021-12-16
US12152087B2 (en) 2024-11-26
IL282231B1 (en) 2025-03-01
AU2019362389A1 (en) 2021-06-03
PL3866931T3 (pl) 2023-06-19
SG11202103726RA (en) 2021-05-28
DK3866931T3 (da) 2023-04-24
JP2022512736A (ja) 2022-02-07
MX2021004474A (es) 2021-08-24
AU2019362389B2 (en) 2024-12-12
CA3116198A1 (fr) 2020-04-23
FI3866931T3 (fi) 2023-05-10
ES2942468T3 (es) 2023-06-01
EP3866931A1 (fr) 2021-08-25
IL282231B2 (en) 2025-07-01
WO2020079165A1 (fr) 2020-04-23
CN112930214A (zh) 2021-06-08
CN112930214B (zh) 2025-05-16
EP3866931B1 (fr) 2023-02-15
JP2024150488A (ja) 2024-10-23
HUE061801T2 (hu) 2023-08-28
BR112021007060A2 (pt) 2021-07-20
US20250115637A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
IL286833A (en) Compositions containing brazzein
PL3844147T3 (pl) Związki chemiczne
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52489A (fr) Nouveaux composés
MA52948A (fr) Composés
EP3720430A4 (fr) Composés benzocarbonyle
EP3802467A4 (fr) Composés spirocycliques
MA55131A (fr) Nouveaux composés hétérocycliques
EP3781156A4 (fr) Composés spirocycliques
MA51669A (fr) Composés
MA44233A (fr) Nouveaux composés
EP3494121A4 (fr) Composés contenant du bore
DK3692040T3 (da) Kemiske forbindelser
MA53003A (fr) Composés
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
DK3866931T3 (da) Forbindelser indeholdende deuterium
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
EP3445750A4 (fr) Composés thérapeutiques
MA47420A (fr) Composés inhibiteurs d'oga
EP3315430A4 (fr) Contenant
EP3707181A4 (fr) Compositions durcissables contenant des composés thiol
EP3728289A4 (fr) Composés optimisés
EP3464336A4 (fr) Composés
EP3897732A4 (fr) Composition contenant des cannabinoïdes
MA52946A (fr) Composés